Compare ARLP & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | KRYS |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 6.3B |
| IPO Year | 1999 | 2017 |
| Metric | ARLP | KRYS |
|---|---|---|
| Price | $24.13 | $244.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $29.50 | ★ $214.22 |
| AVG Volume (30 Days) | 232.1K | ★ 277.7K |
| Earning Date | 10-27-2025 | 11-03-2025 |
| Dividend Yield | ★ 9.95% | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 1.89 | ★ 6.66 |
| Revenue | ★ $2,249,390,000.00 | $373,164,000.00 |
| Revenue This Year | N/A | $36.14 |
| Revenue Next Year | $3.41 | $41.80 |
| P/E Ratio | ★ $12.74 | $36.79 |
| Revenue Growth | N/A | ★ 54.51 |
| 52 Week Low | $22.20 | $122.80 |
| 52 Week High | $30.56 | $248.60 |
| Indicator | ARLP | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 81.72 |
| Support Level | $24.02 | $213.83 |
| Resistance Level | $24.60 | $241.65 |
| Average True Range (ATR) | 0.47 | 7.53 |
| MACD | 0.04 | 2.17 |
| Stochastic Oscillator | 66.92 | 89.34 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties has included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.